Argos Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Argos Therapeutics's estimated annual revenue is currently $7.5M per year. 0
- Argos Therapeutics's total funding is $238.9M.
Employee Data
- 00
Argos Therapeutics's People
| Name | Title | Email/Phone |
|---|
Argos Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Argos Therapeutics?
Argos Therapeutics, Inc., formerly Merix Bioscience, is a pioneer in immunotherapy. Our focus is bringing to market therapeutic options that not only offer new promise for treatment of intractable diseases, but also an improved safety profile and better patient quality of life during treatment.
keywords:N/A
$238.9M
Total Funding
N/A
Number of Employees
$7.5M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Argos Therapeutics News
Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech,...
mRNA Cancer Vaccines and Therapeutics Market Sets the Table for Continued Growth | Argos Therapeutics, Moderna Therapeutics, eTheRNA.
Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech,...
Argos Therapeutics Inc., biotechnology company headquartered in Durham, North Carolina, announced that a Hong Kong company purchased 7.5 million shares of stock for $1.5 million, according to a filing with the Securities and Exchange Commission. The sale of the shares is expected to close on or ...
Argos Therapeutics, Inc. (Nasdaq: ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it has entered into a securities purc ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.5M | 0 | N/A | $1.7M |
#2 | $111.7M | 0 | N/A | N/A |
#3 | $10.4M | 0 | N/A | $85.1M |
#4 | $0.1M | 1 | 0% | N/A |
#5 | $0.1M | 1 | -50% | N/A |